These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31861655)

  • 1. Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.
    Heib A; Niro G; Weck SC; Koppermann S; Ducho C
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31861655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoribosylated Analogues of Muraymycin Nucleoside Antibiotics.
    Wiegmann D; Koppermann S; Ducho C
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30486316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogues of Muraymycin Nucleoside Antibiotics with Epimeric Uridine-Derived Core Structures.
    Spork AP; Koppermann S; Schier Née Wohnig S; Linder R; Ducho C
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30400295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified Novel Muraymycin Analogues; using a Serine Template Strategy for Linking Key Pharmacophores.
    Patel B; Kerr RV; Malde AK; Zunk M; Bugg TDH; Grant G; Rudrawar S
    ChemMedChem; 2020 Aug; 15(15):1429-1438. PubMed ID: 32476294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics.
    Koppermann S; Cui Z; Fischer PD; Wang X; Ludwig J; Thorson JS; Van Lanen SG; Ducho C
    ChemMedChem; 2018 Apr; 13(8):779-784. PubMed ID: 29438582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Medicinal Chemistry of Muraymycins, Nucleoside Antibiotics.
    Katsuyama A; Ichikawa S
    Chem Pharm Bull (Tokyo); 2018; 66(2):123-131. PubMed ID: 29386462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of nucleoside antibacterial natural product antibiotics.
    Bugg TDH; Kerr RV
    J Antibiot (Tokyo); 2019 Dec; 72(12):865-876. PubMed ID: 31471595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
    Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
    Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial Nucleoside Natural Products Inhibiting Phospho-MurNAc-Pentapeptide Translocase; Chemistry and Structure-Activity Relationship.
    Ichikawa S; Yamaguchi M; Matsuda A
    Curr Med Chem; 2015; 22(34):3951-79. PubMed ID: 26282943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.
    Kwak SH; Lim WY; Hao A; Mashalidis EH; Kwon DY; Jeong P; Kim MJ; Lee SY; Hong J
    Eur J Med Chem; 2021 Apr; 215():113272. PubMed ID: 33607457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Merging Natural Products: Muraymycin-Sansanmycin Hybrid Structures as Novel Scaffolds for Potential Antibacterial Agents.
    Niro G; Weck SC; Ducho C
    Chemistry; 2020 Dec; 26(70):16875-16887. PubMed ID: 32897546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.
    Mashalidis EH; Lee SY
    J Mol Biol; 2020 Aug; 432(18):4946-4963. PubMed ID: 32199982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors.
    Tanino T; Al-Dabbagh B; Mengin-Lecreulx D; Bouhss A; Oyama H; Ichikawa S; Matsuda A
    J Med Chem; 2011 Dec; 54(24):8421-39. PubMed ID: 22085339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Products at Work: Structural Insights into Inhibition of the Bacterial Membrane Protein MraY.
    Koppermann S; Ducho C
    Angew Chem Int Ed Engl; 2016 Sep; 55(39):11722-4. PubMed ID: 27511599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
    Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
    Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muraymycin nucleoside-peptide antibiotics: uridine-derived natural products as lead structures for the development of novel antibacterial agents.
    Wiegmann D; Koppermann S; Wirth M; Niro G; Leyerer K; Ducho C
    Beilstein J Org Chem; 2016; 12():769-795. PubMed ID: 27340469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of the nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitors.
    Dini C; Collette P; Drochon N; Guillot JC; Lemoine G; Mauvais P; Aszodi J
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1839-43. PubMed ID: 10969981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caprazamycins: Biosynthesis and structure activity relationship studies.
    Wiker F; Hauck N; Grond S; Gust B
    Int J Med Microbiol; 2019 Jul; 309(5):319-324. PubMed ID: 31138496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Resistance during Muraymycin Biosynthesis: a Complementary Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and Distinct Temporal Order.
    Cui Z; Wang XC; Liu X; Lemke A; Koppermann S; Ducho C; Rohr J; Thorson JS; Van Lanen SG
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis.
    Hering J; Dunevall E; Ek M; Brändén G
    Drug Discov Today; 2018 Jul; 23(7):1426-1435. PubMed ID: 29778697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.